SEC 10K
AOXY reports $1.2M in annual revenue with 15% YoY growth, but posts $450K net loss due to R&D spend
AOXY shows modest top-line growth but concerning cash burn. The 15% revenue increase to $1.2M is overshadowed by a widening net loss ($450K vs $320K) as R&D spend accelerates ahead of key product launches. The company's military contract pipeline and FDA fast-track designation provide catalysts, but with only $320K cash and heavy customer concentration, near-term liquidity risks dominate. Sector observers will watch whether AOXY can secure bridge financing before Q4 cash crunch.
- Ticker
- AOXY
- Form
- 10-K
Filing analysis
AOXY shows modest top-line growth but concerning cash burn. The 15% revenue increase to $1.2M is overshadowed by a widening net loss ($450K vs $320K) as R&D spend accelerates ahead of key product launches. The company's military contract pipeline and FDA fast-track designation provide catalysts, but with only $320K cash and heavy customer concentration, near-term liquidity risks dominate. Sector observers will watch whether AOXY can secure bridge financing before Q4 cash crunch.
All AOXY markets, filings and insider activity →
Source: Original SEC filing